This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
== Quantum mechanics == Aggregated systems of subatomic particles described by quantum mechanics (quarks inside nucleons, nucleons inside atomic nuclei, electrons inside atoms, molecules, or atomic clusters) are found to have many distinguishable states. Of these, one (or a small degenerate set) is indefinitely stable: the ground state or global minimum. All other states besides the ground state (or those degenerate with it) have higher energies. Of all these other states, the metastable states are the ones having lifetimes lasting at least 102 to 103 times longer than the shortest lived states of the set. A metastable state is then long-lived (locally stable with respect to configurations of 'neighbouring' energies) but not eternal (as the global minimum is). Being excited – of an energy above the ground state – it will eventually decay to a more stable state, releasing energy. Indeed, above absolute zero, all states of a system have a non-zero probability to decay; that is, to spontaneously fall into another state (usually lower in energy). One mechanism for this to happen is through tunnelling.
== S == SAD – Selected area diffraction SAED – Selected area electron diffraction SAM – Scanning Auger microscopy SANS – Small angle neutron scattering SAXS – Small angle X-ray scattering SCANIIR – Surface composition by analysis of neutral species and ion-impact radiation SCEM – Scanning confocal electron microscopy SE – Spectroscopic ellipsometry SEC – Size exclusion chromatography SEIRA – Surface enhanced infrared absorption spectroscopy SEM – Scanning electron microscopy SERS – Surface enhanced Raman spectroscopy SERRS – Surface enhanced resonance Raman spectroscopy SESANS – Spin Echo Small Angle Neutron Scattering SEXAFS – Surface extended X-ray absorption fine structure SICM – Scanning ion-conductance microscopy SIL – Solid immersion lens SIM – Solid immersion mirror SIMS – Secondary ion mass spectrometry SNMS – Sputtered neutral species mass spectrometry SNOM – Scanning near-field optical microscopy SPECT – Single-photon emission computed tomography SPM – Scanning probe microscopy SRM-CE/MS – Selected-reaction-monitoring capillary-electrophoresis mass-spectrometry SSNMR – Solid-state nuclear magnetic resonance Stark spectroscopy STED – Stimulated emission depletion microscopy STEM – Scanning transmission electron microscopy STM – Scanning tunneling microscopy STS – Scanning tunneling spectroscopy SXRD – Surface X-ray diffraction
Nadolol, sold under the brand name Corgard among others, is a medication used to treat high blood pressure, heart pain, atrial fibrillation, and some inherited arrhythmic syndromes. It has also been used to prevent migraine headaches and complications of cirrhosis. It is taken orally. Common side effects include dizziness, feeling tired, a slow heart rate, and Raynaud syndrome. Serious side effects may include heart failure and bronchospasm. Its use in pregnancy and breastfeeding is of unclear safety. It is a non-selective beta blocker and works by blocking β1-adrenergic receptors in the heart and β2-adrenergic receptors in blood vessels. Nadolol was patented in 1970 and came into medical use in 1978. It is available as a generic medication. In 2020, it was the 340th most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.
A silk biomaterial is a biomaterial made from the structural proteins of silk, primarily silk fibroin and, less often, the associated protein sericin. Most are obtained from the silk cocoons of the silkworm Bombyx mori, although spider silk and the silks of a few other insects are also used. The medical use of silk is far older than the term biomaterial. Silk thread served as a surgical suture for centuries before the protein was first dissolved and cast into films, gels, sponges, fibres and particles.
Sources: en.wikipedia.org
=== Pathogenic fungi === The glyoxylate cycle may serve an entirely different purpose in some species of pathogenic fungi. The levels of the main enzymes of the glyoxylate cycle, ICL and MS, are greatly increased upon contact with a human host. Mutants of a particular species of fungi that lacked ICL were also significantly less virulent in studies with mice compared to the wild type. The exact link between these two observations is still being explored, but it can be concluded that the glyoxylate cycle is a significant factor in the pathogenesis of these microbes.
All security responsibilities were then assumed by the Iraqi Armed Forces and other security agencies, including the Ministry of Interior. The Office of Security Cooperation - Iraq, part of the larger Embassy of the United States, Baghdad held the remaining DOD support personnel, totalling about 1,000 contractors and about 147 DOD uniformed personnel. It operated from ten locations around Iraq, and managed about 370 Foreign Military Sales cases, totaling more than US $9 billion of pending arms sales, citing a February 2012 Congressional Research Service report; training; and follow-on support functions. The biggest program underway was the much-delayed sale of 18 Lockheed Martin F-16 Fighting Falcon fighters.
== Redox activity == Most selenoproteins have a redox function analogous to proteins with Cys active sites. Two residues of Sec can be oxidized to form a diselenide bond (-Se-Se-), the selenium analog of the disulfide bridge. Sec can also form a selenenyl sulfide (-Se-S-) bond with Cys. The Se-H bond is more easily broken than the S-H bond, resulting in higher reactivity of the Sec residue compared to Cys. Also contributing to reactivity is the higher nucleophilicity, acidity, and leaving-group ability of selenolate (R-Se-) compared to thiolate (R-S-). The Se-Se bond is also weaker than the S-S bond. The result is that the Sec can easily be oxidized and reduced, without much change of getting stuck in one state. Sec is not more reactive than Cys in every single aspect. Selanyl radicals generated from Sec is less prone to attacking aromatic amino acid residues and protein Cα atoms than the thiyl radicals generated from Cys. This offers redox-active selenoproteins some protection from breaking itself apart compared to their cystine-only relatives.
In January 2022, the U.S. DEA proposed scheduling five additional psychedelic tryptamines, including DiPT, 4-HO-DiPT (4-OH-DiPT), 5-MeO-DET, 5-MeO-MiPT, and 5-MeO-AMT. However, they subsequently withdrew this proposal in July 2022. This followed pushback and opposition from the psychedelic community and medical industry. In December 2023, the U.S. DEA proposed scheduling the DOx psychedelics DOC and DOI. As of late 2025, despite opposition to this proposal as well, these drugs are poised to become controlled substances in the near future.
VFFAEDVGSNKGAIIGLMVGGVVIAT In relation to the secondary structure of p3 peptide, it is thought that after the cleavage by the α- and γ- secretases and extraction from the membrane it would convert quickly from the α-helix conformation it has when it is part of APPsα sequence to a β-hairpin structure. Then, this highly hydrophobic monomer would rapidly evolve into fibrils with no soluble intermediate forms, the ones related to amyloid’s structure. The main reason why p3 does not aggregate in amyloidogenic forms while Aβ does, is that the N-terminal domain Aβ1–16, which is present in Aβ’s sequence but not in p3's one, is known to protect the hydrophobic core of the oligomers from being dissolved by the watered medium. So, p3 peptide oligomers would likely expose hydrophobic residues to water and would be less stable. As a consequence, p3 peptide structural determinants can assemble into fibrils, but no oligomeric forms have been identified. That is why p3 peptide represents the benign form of amyloid.
Sources: en.wikipedia.org
=== Preclinical === 2-Bromo-LSD (bromolysergide; BOL-148; BETR-001, TD-0148A) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions ART-2612 (ART2612) – FABP5 inhibitor [25] BMB-202 – serotonin 5-HT2A receptor agonist [26] Cycloserine/lurasidone (NRX-101) – combination of cycloserine (NMDA receptor partial agonist) and lurasidone (atypical antipsychotic or non-selective monoamine receptor modulator) [27] Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (H1 receptor antagonist, muscarinic acetylcholine receptor antagonist, serotonin receptor antagonist, other actions) and prazosin (α1-adrenergic receptor antagonist) [28] GM-3009 (ibogaine analogue(s); GMX-3009) – various actions Leu-enkephalin (leucine enkephalin; Envelta; METDoloron; NES-100; NM-0127; NM-127; PES200) – δ-opioid receptor agonist [29] Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor, antiglucocorticoid) and oxazepam (GABAA receptor positive allosteric modulator, benzodiazepine) Midomafetamine microneedle transdermal patch (MDMA; "ecstasy") – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen NB-127 – undefined mechanism of action [30] NNI-351 – DYRK kinase inhibitor, nerve growth factor (NGF) stimulant [31] Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent [32] Research programme: neurotransmitter modulators - Awakn Life Sciences (AWKN-SDN-14) – serotonin–norepinephrine–dopamine reuptake inhibitors [33] TN-001 – non-hallucinogenic serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist and neuroplastogen
== Applications == Due to its contribution to fibrinolysis, tissue plasminogen activator is used medically to treat blood clot-related disorders including thrombotic or embolic stroke, myocardial infarction, and pulmonary embolism. It is manufactured using recombinant techniques and is sold as alteplase, reteplase, and tenecteplase. Alteplase was the first of these versions to go on the market, and has the same structure as tPA. Reteplase and tenecteplase both received FDA approval after alteplase, and have nonidentical structures to tPA. These recombinant forms of tPA have been shown to have a longer half-life in the blood and greater resistance to inhibition, resulting in an increased capacity to treat thrombolytic diseases. Urokinase is similarly used in the medical field, specifically for the treatment of pulmonary embolism.
=== Awards === At E3 2006, BioShock was given several "Games of the Show" awards from various online gaming sites, including GameSpot, IGN, GameSpy and GameTrailers's Trailer of the Year. After the game's release, the 2007 Spike TV Video Game Awards selected BioShock as Game of the Year, Best Xbox 360 Game, and Best Original Score, and nominated it for four awards: Best Shooter, Best Graphics, Best PC Game, and Best Soundtrack. The game also won the 2007 BAFTA "Best Game" award. X-Play also selected it as "Game of the Year", "Best Original Soundtrack", "Best Writing/Story", and "Best Art Direction". Game Informer named BioShock its Game of the Year for 2007. At IGN's "Best of 2007" BioShock was nominated for Game of The Year 2007, and won the award for PC Game of the Year, Best Artistic Design, and Best Use of Sound. GameSpy chose it as the third-best game of the year and gave BioShock the awards for Best Sound, Story, and Art Direction. GameSpot awarded the game for Best Story, while GamePro gave BioShock the Best Story, Xbox 360 and Best Single-Player Shooter awards. BioShock won the "Best Visual Art", "Best Writing", and "Best Audio" awards at the 2008 Game Developers Choice Awards.
== Departments == Division of Basic Medical Sciences I Department of Biochemistry Department of General Biology Department of Medical Physics Division of Basic Medical Sciences II Department of Anatomy Department of General Pharmacology Department of Physiology Division of Clinical Laboratories Department of Microbiology Department of Nuclear Medicine Department of Pathology Department of Public Health Department of Radiology Division of Internal Medicine Ι Department of Internal Medicine Division of Paediatrics & Obstetrics – Gynaecology Department of Obstetrics - Gynecology Department of Paediatric Surgery Department of Paediatrics Division of Surgery Department of Anaesthesiology and Intensive Care Department of Cardiothoracic Surgery Department of Neurosurgery Department of Ophthalmology Department of Orthopaedics Department of Otorhinolaryngology Department of Surgery Department of Urology Department of Vascular Surgery
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.